113 related articles for article (PubMed ID: 38354330)
1. Sunitinib in Patients With Breast Cancer With
Calfa CJ; Rothe M; Mangat PK; Garrett-Mayer E; Ahn ER; Burness ML; Gogineni K; Rohatgi N; Al Baghdadi T; Conlin A; Gaba A; Hamid O; Krishnamurthy J; Gavini NJ; Gold PJ; Rodon J; Rueter J; Thota R; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
JCO Precis Oncol; 2024 Feb; 8():e2300513. PubMed ID: 38354330
[TBL] [Abstract][Full Text] [Related]
2. Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With
Cannon TL; Rothe M; Mangat PK; Garrett-Mayer E; Chiu VK; Hwang J; Vijayvergia N; Alese OB; Dib EG; Duvivier HL; Klute KA; Sahai V; Ahn ER; Bedano P; Behl D; Sinclair S; Thota R; Urba WJ; Yang ES; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
J Clin Oncol; 2024 May; ():JCO2302078. PubMed ID: 38748939
[TBL] [Abstract][Full Text] [Related]
3. Regorafenib in Patients With Solid Tumors With
Sahai V; Rothe M; Mangat PK; Garrett-Mayer E; Suhag V; Dib EG; Mehmi I; Kadakia KC; Pisick E; Duvivier HL; Le P; Li R; Michelin DP; Wilcox RE; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
JCO Precis Oncol; 2024 Apr; 8():e2300527. PubMed ID: 38603652
[TBL] [Abstract][Full Text] [Related]
4. Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With
Ganti AK; Rothe M; Mangat PK; Garrett-Mayer E; Dib EG; Duvivier HL; Ahn ER; Behl D; Borghaei H; Balmanoukian AS; Gaba A; Li R; Osei-Boateng K; Thota R; Grantham GN; Gregory A; Halabi S; Schilsky RL
JCO Precis Oncol; 2023 Jun; 7():e2300041. PubMed ID: 37315265
[TBL] [Abstract][Full Text] [Related]
5. Talazoparib in Patients With Solid Tumors With
Srkalovic G; Rothe M; Mangat PK; Garrett-Mayer E; Ahn ER; Brouse G; Chan J; Mehmi I; Khalil M; Duvivier HL; Gaba A; Leuva H; Thota R; Yost KJ; Grantham GN; Gregory A; Hinshaw DC; Halabi S; Schilsky RL
JCO Precis Oncol; 2024 Jun; 8():e2400026. PubMed ID: 38865672
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With
Rohatgi N; Rothe M; Mangat PK; Garrett-Mayer E; Meric-Bernstam F; Pisick E; Alese OB; Reynolds CM; Thota R; Vaccaro GM; von Mehren M; Arend RC; Chiu VK; Duvivier HL; Gold PJ; Hack K; Marr AS; Winer A; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
JCO Precis Oncol; 2023 Sep; 7():e2300279. PubMed ID: 38039429
[TBL] [Abstract][Full Text] [Related]
7. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With
Meric-Bernstam F; Rothe M; Mangat PK; Garrett-Mayer E; Gutierrez R; Ahn ER; Cannon TL; Powell S; Krauss JC; Reynolds CM; von Mehren M; Behl D; Calfa CJ; Duvivier HL; Kaplan HG; Livingston MB; Sharma MR; Urba WJ; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
JCO Precis Oncol; 2023 Sep; 7():e2300385. PubMed ID: 38096472
[TBL] [Abstract][Full Text] [Related]
8. Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With
Klute KA; Rothe M; Garrett-Mayer E; Mangat PK; Nazemzadeh R; Yost KJ; Duvivier HL; Ahn ER; Cannon TL; Alese OB; Krauss JC; Thota R; Calfa CJ; Denlinger CS; O'Lone R; Halabi S; Grantham GN; Schilsky RL
JCO Precis Oncol; 2022 Nov; 6():e2200191. PubMed ID: 36409971
[TBL] [Abstract][Full Text] [Related]
9. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With
Ahn ER; Rothe M; Mangat PK; Garrett-Mayer E; Ali-Ahmad HM; Chan J; Maitland ML; Patel SR; Reese Z; Balmanoukian AS; Drescher CW; Li R; Tsimberidou AM; Leath CA; O'Lone R; Grantham GN; Halabi S; Schilsky RL
JCO Precis Oncol; 2023 Apr; 7():e2200609. PubMed ID: 37027810
[TBL] [Abstract][Full Text] [Related]
10. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
Duvivier HL; Rothe M; Mangat PK; Garrett-Mayer E; Ahn ER; Al Baghdadi T; Alva AS; Dublis SA; Cannon TL; Calfa CJ; Li R; Behl D; Chiu VK; Gold PJ; Marr AS; Mileham KF; Powell SF; Rodon J; Thota R; Grantham GN; Gregory A; Hinshaw DC; Halabi S; Schilsky RL
J Clin Oncol; 2023 Nov; 41(33):5140-5150. PubMed ID: 37561967
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Al Baghdadi T; Garrett-Mayer E; Halabi S; Mangat PK; Rich P; Ahn ER; Chai S; Rygiel AL; Osayameh O; Antonelli KR; Islam S; Bruinooge SS; Schilsky RL
Target Oncol; 2020 Dec; 15(6):743-750. PubMed ID: 33068284
[TBL] [Abstract][Full Text] [Related]
13. Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients.
Erber R; Rübner M; Davenport S; Hauke S; Beckmann MW; Hartmann A; Häberle L; Gass P; Press MF; Fasching PA
Breast Cancer Res Treat; 2020 Nov; 184(2):311-324. PubMed ID: 32852708
[TBL] [Abstract][Full Text] [Related]
14. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With
Gupta R; Meric-Bernstam F; Rothe M; Garrett-Mayer E; Mangat PK; D'Andre S; Ahn ER; O'Lone R; Halabi S; Grantham GN; Schilsky RL
JCO Precis Oncol; 2022 Oct; 6():e2200306. PubMed ID: 36315917
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Alva AS; Mangat PK; Garrett-Mayer E; Halabi S; Hansra D; Calfa CJ; Khalil MF; Ahn ER; Cannon TL; Crilley P; Fisher JG; Haslem DS; Shrestha S; Antonelli KR; Butler NL; Warren SL; Rygiel AL; Ranasinghe S; Bruinooge SS; Schilsky RL
J Clin Oncol; 2021 Aug; 39(22):2443-2451. PubMed ID: 33844595
[TBL] [Abstract][Full Text] [Related]
16. Palbociclib in Patients With Non-Small-Cell Lung Cancer With
Ahn ER; Mangat PK; Garrett-Mayer E; Halabi S; Dib EG; Haggstrom DE; Alguire KB; Calfa CJ; Cannon TL; Crilley PA; Gaba AG; Marr AS; Sangal A; Thota R; Antonelli KR; Islam S; Rygiel AL; Bruinooge SS; Schilsky RL
JCO Precis Oncol; 2020 Nov; 4():757-766. PubMed ID: 35050752
[TBL] [Abstract][Full Text] [Related]
17. Lucitanib for the Treatment of HR
Hui R; Pearson A; Cortes J; Campbell C; Poirot C; Azim HA; Fumagalli D; Lambertini M; Daly F; Arahmani A; Perez-Garcia J; Aftimos P; Bedard PL; Xuereb L; Scheepers ED; Vicente M; Goulioti T; Loibl S; Loi S; Pierrat MJ; Turner NC; Andre F; Curigliano G
Clin Cancer Res; 2020 Jan; 26(2):354-363. PubMed ID: 31619444
[TBL] [Abstract][Full Text] [Related]
18. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.
Konecny GE; Finkler N; Garcia AA; Lorusso D; Lee PS; Rocconi RP; Fong PC; Squires M; Mishra K; Upalawanna A; Wang Y; Kristeleit R
Lancet Oncol; 2015 Jun; 16(6):686-94. PubMed ID: 25981814
[TBL] [Abstract][Full Text] [Related]
19. CCND1 and FGFR1 gene amplifications are associated with reduced benefit from aromatase inhibitors in metastatic breast cancer.
Aleksakhina SN; Kramchaninov MM; Mikushina AD; Kubrina SE; Petkau VV; Ivantsov AO; Moiseyenko VM; Imyanitov EN; Iyevleva AG
Clin Transl Oncol; 2021 Apr; 23(4):874-881. PubMed ID: 32880048
[TBL] [Abstract][Full Text] [Related]
20. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Abou-Alfa GK; Sahai V; Hollebecque A; Vaccaro G; Melisi D; Al-Rajabi R; Paulson AS; Borad MJ; Gallinson D; Murphy AG; Oh DY; Dotan E; Catenacci DV; Van Cutsem E; Ji T; Lihou CF; Zhen H; Féliz L; Vogel A
Lancet Oncol; 2020 May; 21(5):671-684. PubMed ID: 32203698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]